SCHEMBL19296129

SCHEMBL19296129

CCOC(=O)CC(=O)C[C@](C)(N[S@+]([O-])C(C)(C)C)c1cc(Br)ccc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.35
ALOX5 P09917 6/20 0.34
PTGES O14684 2/20 0.34
KAT6A Q92794 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.32
KMT2A Q03164 2/20 0.32
HPGD P15428 1/20 0.32
KDM4E B2RXH2 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
GAA P10253 1/20 0.31
TP53 P04637 1/20 0.31
NLRP3 Q96P20 1/20 0.31
EGFR P00533 1/20 0.31
ERBB3 P21860 1/20 0.31
MEN1 O00255 1/20 0.30
S1PR4 O95977 1/20 0.30
LMNA P02545 1/20 0.30
S1PR1 P21453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2591587 0.94 BACE1 (0.36) BACE1ALOX5PTGESKAT6AALDH1A1
SCHEMBL2591589 0.94 BACE1 (0.36) BACE1ALOX5PTGESKAT6AALDH1A1
SCHEMBL2591584 0.94 BACE1 (0.36) BACE1ALOX5PTGESKAT6AALDH1A1
SCHEMBL17004602 0.86 BACE1 (0.36) BACE1ALDH1A1MAPTHPGDKDM4E
SCHEMBL17004603 0.86 BACE1 (0.36) BACE1ALDH1A1MAPTHPGDKDM4E
SCHEMBL17004601 0.86 BACE1 (0.36) BACE1ALDH1A1MAPTHPGDKDM4E
SCHEMBL17606998 0.86 PTGDR2 (0.36) BACE1ALDH1A1PTGDR2LMNA
SCHEMBL21433323 0.84 BACE1 (0.45) BACE1ALDH1A1PTGDR2LMNAMAPK1
SCHEMBL15991534 0.84 BACE1 (0.45) BACE1ALDH1A1PTGDR2LMNAMAPK1
SCHEMBL15994984 0.83 BACE1 (0.35) BACE1ALDH1A1MAPTKMT2APTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9868738-B2 Diazine-fused amidines as BACE inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2018-01-16 US disclosed
US-20170247377-A1 DIAZINE-FUSED AMIDINES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-08-31 US disclosed
US-20170247377-A1 DIAZINE-FUSED AMIDINES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247377-A1 DIAZINE-FUSED AMIDINES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE BACE1, BACE2, APP BACE1 1/4885ALOX5 3099/4885PTGES 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.